MMP-8 as a novel therapeutic target in sepsis

MMP-8作为脓毒症的新治疗靶点

基本信息

  • 批准号:
    8245762
  • 负责人:
  • 金额:
    $ 29.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Septic shock is a major public health problem in both adults and children, and consequently there is a need to develop novel targets and therapeutic strategies. Based on microarray-centered clinical studies and follow up animal-centered experiments, we have indentified matrix metallopeptidase-8 (MMP-8) as a candidate target in sepsis pathology. MMP-8 is best known as a neutrophil product that cleaves collagen type 1 during extra-cellular matrix turnover. However, it has now become evident that MMP-8 also modulates acute inflammation and may play a role in sepsis pathology. The overarching hypothesis of this proposal is that MMP-8 expression and activity play a major role in sepsis pathology. We are now proposing to test this hypothesis via four complementary Specific Aims. In Specific Aim 1 we will test the hypothesis that inhibition of MMP-8 activity improves multiple endpoints relevant to sepsis pathology. This Aim will use MMP-8 null animals and a pharmacologic inhibitor of MMP-8 activity. In Specific Aim 2 we will test the hypothesis that developmental age influences the role of MMP-8 in sepsis. This Aim will use a sepsis model adaptable to 1 week old mouse pups, and will also make use of MMP-8 null mice and a pharmacologic inhibitor of MMP-8 activity. In Specific Aim 3 we will test the hypothesis that bone marrow-derived cells are the main source of MMP-8 gene regulation in sepsis. The in vivo experiments for this Aim will involve adoptive transfer of MMP-8 null bone marrow to wild-type mice, and vice versa. The in vitro experiments for this Aim will systematically elucidate the signaling mechanisms that lead to de novo MMP-8 gene expression in neutrophils and monocytes. In Specific Aim 4 we will test the hypothesis that collagen type 1 degradation products are involved in the mechanism by which MMP-8 regulates inflammation. The in vitro experiments for this Aim will test the ability of conditioned media, derived from collagen type 1 coated tissue culture plates treated with activated MMP-8, to activate macrophages. The in vivo experiments for this Aim will measure the response to sepsis in mice having a mutation of collagen type 1, which renders it resistant to cleavage by MMP-8. The major deliverables of this proposal include the establishment of MMP-8 as a novel therapeutic target in sepsis, the elucidation of how development influences the role of MMP-8 in sepsis, the elucidation of the major cellular source of MMP-8 in sepsis, a comprehensive understanding of the signaling mechanisms involved in MMP-8 expression during inflammation, and the establishment of MMP-8-dependent collagen type 1 degradation products as danger associated molecular patterns for the innate immune system. PUBLIC HEALTH RELEVANCE: The deliverable of this program will be the elucidation of a major role for MMP-8 expression and activity in sepsis pathology. Public health will be positively impacted by providing the foundation for the development of a novel therapeutic strategy for clinical sepsis.
描述(由申请人提供):感染性休克是成人和儿童的主要公共卫生问题,因此需要开发新的靶点和治疗策略。基于以基因芯片为中心的临床研究和以动物为中心的后续实验,我们已确定基质金属多肽酶-8(MMP8)是脓毒症病理的候选靶点。基质金属蛋白酶-8最为人所知的是一种中性粒细胞产物,它在细胞外基质转化过程中裂解1型胶原。然而,现在已经很明显,基质金属蛋白酶-8也调节急性炎症,并可能在脓毒症的病理中发挥作用。这一建议的主要假设是,基质金属蛋白酶-8的表达和活性在脓毒症的病理过程中起主要作用。我们现在提议通过四个相辅相成的具体目标来检验这一假设。在特定的目标1中,我们将测试这一假设,即抑制基质金属蛋白酶-8的活性可以改善与脓毒症病理相关的多个终点。这个目标将使用基质金属蛋白酶-8缺失的动物和一种药物抑制基质金属蛋白酶-8的活性。在特定的目标2中,我们将检验发育年龄影响基质金属蛋白酶-8在脓毒症中的作用的假设。这个目标将使用一种适合于一周大的小鼠的脓毒症模型,也将使用MMP8基因缺失的小鼠和一种MMP8活性的药物抑制物。在特定的目标3中,我们将检验骨髓来源的细胞是脓毒症中基质金属蛋白酶-8基因调控的主要来源的假设。为了达到这一目的,体内实验将涉及将MMP-8缺失的骨髓过继转移到野生型小鼠,反之亦然。为了达到这一目的,体外实验将系统地阐明导致中性粒细胞和单核细胞重新表达基质金属蛋白酶-8基因的信号机制。在特定的目标4中,我们将检验这一假设,即1型胶原降解产物参与了基质金属蛋白酶-8调节炎症的机制。为了达到这一目的,体外实验将测试从1型胶原涂层组织培养板中提取的条件培养液,经活化的基质金属蛋白酶-8处理后,激活巨噬细胞的能力。为了达到这个目的,体内实验将测量具有1型胶原突变的小鼠对脓毒症的反应,这种突变使其对基质金属蛋白酶-8的切割具有抵抗力。这一建议的主要成果包括建立一个新的脓毒症治疗靶点,阐明发育如何影响MMP-8在脓毒症中的作用,阐明脓毒症中基质金属蛋白酶-8的主要细胞来源,全面了解炎症过程中参与基质金属蛋白酶-8表达的信号机制,以及建立依赖于基质金属蛋白酶-8的1型胶原降解产物作为先天免疫系统的危险相关分子模式。 公共卫生相关性:这一计划的交付将阐明基质金属蛋白酶-8的表达和活性在脓毒症病理中的主要作用。通过为临床脓毒症的新治疗策略的发展提供基础,将对公共健康产生积极的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HECTOR R. WONG其他文献

HECTOR R. WONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HECTOR R. WONG', 18)}}的其他基金

Sepsis from Bedside to Bench to Bedside
脓毒症从床边到长凳到床边
  • 批准号:
    9898384
  • 财政年份:
    2018
  • 资助金额:
    $ 29.07万
  • 项目类别:
PCSK9 and Pediatric Sepsis-Related MODS
PCSK9 和儿科脓毒症相关 MODS
  • 批准号:
    9756433
  • 财政年份:
    2018
  • 资助金额:
    $ 29.07万
  • 项目类别:
Sepsis from Bedside to Bench to Bedside
脓毒症从床边到长凳到床边
  • 批准号:
    10132344
  • 财政年份:
    2018
  • 资助金额:
    $ 29.07万
  • 项目类别:
Supplement for MIRA award_Wong_2021
MIRA 奖补充材料_Wong_2021
  • 批准号:
    10389655
  • 财政年份:
    2018
  • 资助金额:
    $ 29.07万
  • 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
  • 批准号:
    8841381
  • 财政年份:
    2014
  • 资助金额:
    $ 29.07万
  • 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
  • 批准号:
    9234036
  • 财政年份:
    2014
  • 资助金额:
    $ 29.07万
  • 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
  • 批准号:
    8695557
  • 财政年份:
    2014
  • 资助金额:
    $ 29.07万
  • 项目类别:
Novel diagnostic and stratification tools for septic shock
感染性休克的新型诊断和分层工具
  • 批准号:
    8970115
  • 财政年份:
    2014
  • 资助金额:
    $ 29.07万
  • 项目类别:
Stratification of pediatric septic shock
小儿感染性休克的分层
  • 批准号:
    8366660
  • 财政年份:
    2012
  • 资助金额:
    $ 29.07万
  • 项目类别:
Stratification of pediatric septic shock
小儿感染性休克的分层
  • 批准号:
    8525406
  • 财政年份:
    2012
  • 资助金额:
    $ 29.07万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了